

New Hampshire Medicaid Fee-for-Service Program

Rho Kinase Inhibitor Criteria

Approval Date: January 14, 2022

Medications

Brand Names	Generic Names	Dosage
Rhopressa®	netarsudil	0.02% (0.2 mg/mL) 2.5 mL vial
Rocklatan®	netarsudil/latanoprost	0.02%/0.005% 2.5 mL vial

Indication

Rhopressa® (netarsudil) is indicated to reduce intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).

Rocklatan® (netarsudil/latanoprost) is indicated to indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.

Criteria for Approval

1. The patient has had an adequate trial and failure (within the last 60 days) of a generic prostaglandin inhibitor or beta-adrenergic antagonist

Approval period: One year

Renewal Criteria:

1. Patient must continue to meet above criteria; **AND**
2. Have demonstrated efficacy (e.g., reduction in IOP).

Renewal approval period: One year

Criteria for Denial

Failure to meet criteria for approval.

References

Available upon request.

Proprietary & Confidential

© 2019–2022 Magellan Health, Inc. All rights reserved.

Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc.

Revision History

Reviewed by	Reason for Review	Date Approved
DUR Board	New	03/12/2019
Commissioner Designee	New	04/05/2019
DUR Board	Review	10/28/2019
Commissioner Designee	Approve	12/03/2019
DUR Board	Review	06/30/2020
Commissioner Designee	Approve	08/07/2020
DUR Board	Review	12/02/2021
Commissioner Designee	Approve	01/14/2022